1月5日重要公告一览

Group 1 - Longjian Co., Ltd. reported a net profit of 405 million yuan for 2025, a decrease of 2.05% year-on-year, with operating revenue of 17.685 billion yuan, down 3.31% year-on-year, impacted by industry factors and national macro policies [1] - Dayang Bio's net profit for 2025 is expected to increase by 50.60% to 72.56%, reaching between 96 million and 110 million yuan, driven by strong performance in core products such as potassium carbonate and veterinary raw materials [2] - Dongcheng Pharmaceutical plans to repurchase shares worth between 100 million and 200 million yuan to implement equity incentives and/or employee stock ownership plans [3] Group 2 - Longpan Technology intends to invest up to 2 billion yuan in a high-performance lithium battery cathode material project, with a production capacity of 240,000 tons per year [4] - Jinggong Technology successfully launched its first carbon fiber precursor production line, which began trial production on December 31, 2025, and is now in continuous operation [5] - Shengxing Co. has decided to withdraw from the establishment of a life insurance company due to the lack of approval from regulatory authorities, which will not adversely affect its operations [6] Group 3 - ST Yigou's shareholder restructuring plan has been approved by the court, allowing the company to continue its operations without disruption [7] - Dream Network Technology has entered into a cooperation agreement with Jiangxi Shenzhou Liuhe to jointly develop and produce heavy-duty drone products, with a total development budget of 60 million yuan [8] - Haizheng Pharmaceutical's major shareholder, Zhejiang International Trade Group, plans to transfer 6.06% of its shares through a public solicitation, which will not change the company's controlling shareholder [10] Group 4 - Zhenhua Co. plans to issue convertible bonds to raise up to 878 million yuan for various projects, including a vitamin K3 production project and working capital [11] - Fangda Carbon has decided to terminate its participation in the substantive merger and restructuring of the Shanshan Group due to insufficient due diligence [12] - Xingqi Eye Medicine received approval for a supplementary application for atropine sulfate eye drops, expanding its product specifications [13] Group 5 - Shengyi Technology intends to invest 4.5 billion yuan in a high-performance copper-clad laminate project in Dongguan [14] - China Nuclear Power's Fujian Zhangzhou Nuclear Power Plant Unit 2 has completed its 168-hour full power continuous operation assessment and is ready for commercial operation, increasing the company's operational nuclear units to 27 [15] - Guangdong Electric Power A announced the phased shutdown of its ShaJiao C power plant, which will not affect the company's ongoing operations [16] Group 6 - Century Huatong plans to repurchase shares worth between 300 million and 600 million yuan for equity incentives or employee stock ownership plans [17] - Guoguang Electric's general manager has had his detention lifted and has returned to work, with normal operations resuming [19]